Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pradax for VTE Prophylaxis Post-Total Knee Replacement
NCT00868179Phase 4Withdrawn
- Start
- Apr 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabigatran in thromboembolism. Primary endpoints: Clinical evidence of any deep vein thrombosis, non-fatal pulmonary embolism or death from any causes at 28 days and Major bleeding at 6 months. Planned start Apr 2009; status: withdrawn.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT00868179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868179.